| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $11.5M | -28.6% |
| SG&A Expense | $6.5M | +6.1% |
| Operating Income | -$18.0M | +19.1% |
| Net Income | -$17.1M | +17.6% |
| EPS (Basic) | -$1.57 | +18.7% |
| EPS (Diluted) | -$1.57 | +18.7% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $4.4M | -41.1% |
| Short-term Investments | $5.7M | -65.5% |
| Current Assets | $10.8M | -57.2% |
| Total Assets | $11.0M | -56.8% |
| Current Liabilities | $4.5M | +3.9% |
| Total Liabilities | $4.5M | +2.7% |
| Stockholders' Equity | $6.5M | -69.2% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$15.7M | +12.0% |
| Capital Expenditures | $2K | -86.4% |
| Investing Cash Flow | $11.1M | +228.2% |
| Financing Cash Flow | $1.5M | +2145.9% |
| Free Cash Flow | -$15.7M | +12.0% |